1. Background {#sec1}
=============

Extremity chronic osteomyelitis (COM), characterized by inflammatory associated bone destruction with concurrent of new bone formation, usually arises as a sequelae or complication following trauma or orthopaedic surgery \[[@B1]\]. Currently, COM remains to be one of the most challenging disorders in front of orthopaedists, owing to its long disease course, complex in treatment with a higher risk of infection recurrence \[[@B2]\]. In addition, COM also means a catastrophic consequence for patients. Firstly, COM patients have higher incidences of physical and psychological disabilities \[[@B3]\]. Secondly, recent studies have demonstrated that patients with COM might suffer from increased susceptibility to other accompanying diseases, such as rheumatoid arthritis \[[@B4]\], acute pancreatitis \[[@B5]\], diabetes mellitus \[[@B6]\], and intracerebral hemorrhage \[[@B7]\]. Thirdly, diagnosis, treatment, and rehabilitation of COM bring great socioeconomic burdens \[[@B8]\]. Therefore, in addition to clinical studies, great efforts should be taken to investigate pathogenesis of this disorder in order to better solve COM related problems.

Pathogenesis of COM is linked to both environmental and host factors. As an important aspect of host factors, genetic variations play a vital role in the occurrence and development of COM. Recently, growing evidence has revealed that several single nucleotide polymorphisms (SNPs) may be correlated with the risk of developing COM, such as vitamin D receptor (VDR) genes*TaqI*(rs731236) and*FokI*(rs2228570) \[[@B9]\],*cyclooxygenase-2* (COX-2) gene rs689466 \[[@B10]\],*tissue plasminogen activator* (*tPA*) gene*Alu* insertion/deletion (rs4646972) \[[@B11]\], and*matrix metalloprotease 1*(*MMP-1*) gene rs1799750 \[[@B12]\].

It is known that interleukin-1 (IL-1) family cytokines involve in inflammation and immune-regulation and act as an important role in innate and adaptive immunity. Recent studies have indicated that IL-1 can directly affect bone homeostasis, and dysregulation of IL-1 has been proved to be associated with bone disorders \[[@B13]\]. IL-1 exists in two distinct forms, IL-1*α* and IL-1*β*, the latter of which has been reported to be involved in the pathogenesis of OM in recent animal studies \[[@B13], [@B14]\]. IL-1*β* cytokine is encoded by IL-1*β* gene, which is a highly polymorphic. After reviewing previously published studies, we found that four SNPs (rs16944, rs1143627, rs1143634, and rs2853550) located in IL-1*β* gene were the most frequently investigated in relation to the development of inflammatory diseases, such as pediatric Helicobacter pylori infection \[[@B15]\], congenital cytomegalovirus infection \[[@B16]\], septic shock \[[@B17]\], and seasonal influenza A/H3N2 virus infection \[[@B18]\].

Based on the recent outcomes regarding the fact that IL-1*β* participates in the pathogenesis of mice OM as well as the already established evidence that IL-1*β* polymorphisms are linked to inflammatory disorders, we hypothesized that IL-1*β* gene polymorphisms may be associated with COM development. Therefore, the current study aimed to investigate potential relationships between IL-1*β* gene polymorphisms (rs16944, rs1143627, rs1143634, and rs2853550) and the risks of developing COM in Chinese Han population.

2. Patients and Methods {#sec2}
=======================

2.1. Study Design, Population, and Setting {#sec2.1}
------------------------------------------

This study was designed as a case-control report. Participants were Chinese Han population with ethnicity of Asian. Eligible patients were those who sought medical attention for COM between August 2013 and October 2015 in Nanfang Hospital, Southern Medical University, a tertiary medical center in southern China. Diagnosis of COM was established based on any of the following three points: (1) histopathological examination of intraoperative specimen confirms infection, (2) a definite sinus or fistula connects directly to the bone or orthopaedic implant, and (3) cultures from at least two infection sites reveal the same pathogen. Eligible healthy controls, confirmed by physical examination center of our hospital, were those without any diseases or diseases histories. All the participants or legal guardian signed informed consent and the study was approved by medical ethics committee of the hospital.

2.2. SNP Genotyping {#sec2.2}
-------------------

Ethylene diamine tetraacetic acid (EDTA) peripheral blood samples (2 ml) were collected for each participant. Four tag SNPs of the IL-1*β* gene (rs16944, rs1143627, rs1143634, and rs2853550) were genotyped using the Multiplex SNaPshot system (Applied Biosystems, Foster City, USA). The forward (F), reverse (R), and extension primers used for polymerase chain reaction (PCR) and extension reactions were listed in [Table 1](#tab1){ref-type="table"}. Detailed study protocol was described previously \[[@B9]\].

2.3. Primary and Secondary Outcomes {#sec2.3}
-----------------------------------

Primary outcomes were comparisons regarding genotype distribution, mutant allele frequency, and four genetic models (dominant, recessive, homozygous, and heterozygous models) of the four IL-1*β* gene SNPs between patients and healthy controls. Secondary outcomes were comparisons of clinical features (age, sex ratio, positive rate of culture, percentage of polymicrobial infection, preoperative serum levels of white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), tumor necrosis factor-*α* (TNF-*α*), and serum amyloid A (SAA)) among different genotypes of the 4 IL-1*β* gene polymorphisms in the patient group.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical Product and Service Solutions version 13.0 (SPSS Inc., IL, USA) was used to conduct statistical analysis. Kolmogorov-Smirnov test was used to assess data distribution for normality. Continuous variables were presented as mean ± standard deviation or median with interquartile range (IQR) depending on data distribution. For normally distributed data, Student\'s t-test or one-way analysis of variance (ANOVA) was used to compare between 2 different groups or among over 2 groups. Otherwise, Mann-Whitney U test or Kruskal-Wallis H test was applied. Dichotomous variables were expressed as percentages and compared by Chi-square test or Fisher exact test.

Genotype distribution of healthy controls was tested for the confirmation to Hardy-Weinberg equilibrium (HWE) using the Chi-square test. The Chi-square test or Fisher exact test was used to compare genotype distributions and frequencies of mutant allele between the two groups. Binary logistic regression analysis with gender, age, and genotype distribution as covariates was used to evaluate potential associations between the four gene polymorphisms and the risk of developing COM by four genetic models, with corresponding odds ratios (ORs) and 95% confidence intervals (CIs). A*P* value of less than 0.05 was defined as statistical significance.

3. Results {#sec3}
==========

3.1. Demographics {#sec3.1}
-----------------

Altogether 233 patients (185 males and 48 females) with extremity COM and 200 healthy controls (147 males and 53 females) were included. The gender ratio between the two groups revealed no statistical difference (3.85 versus 2.77, *χ*^2^ = 2.094,*P* = 0.148). In addition, no significant difference was identified regarding the median age between the two groups, either (patient group: 42 years, IQR 28.50-54.00 versus control group: 41 years, IQR 36.25--47.00, Z = -0.169,*P* = 0.866).

3.2. Clinical Features of COM {#sec3.2}
-----------------------------

COM clinical features of this Chinese cohort were described previously \[[@B9]\]. Posttraumatic OM was the most frequent type of COM (81.12%), which was primarily following open injury (66.30%). Tibia was the most common infection site (48.51%), followed by femur (29.70%), and toes and metatarsal bones (8.42%), respectively. Positive rate of intraoperative specimen culture was 64.74%, with monomicrobial infection accounted for 78.57%.*Staphylococcus aureus*(32.95%) lay in the top of the detected pathogen.

3.3. Frequency of the Four IL-1*β* Gene Polymorphisms in the Two Groups {#sec3.3}
-----------------------------------------------------------------------

All genotyped four IL-1*β* gene SNPs were in HWE for healthy controls (For rs16944, *P*~(HWE)~ = 0.161, for rs1143627, *P*~(HWE)~ = 0.399, for rs1143634, *P*~(HWE)~ = 0.829, and for rs2853550, *P*~(HWE)~ = 0.429).

As revealed in [Table 2](#tab2){ref-type="table"}, significant associations were found between rs16944 SNP and susceptibility to COM by dominant model (*P* = 0.026, OR = 1.698, 95% CI 1.065-2.707) and heterozygous model (*P* = 0.030, OR = 1.733, 95% CI 1.055-2.847), suggesting that population with the genotype of AG may be a group in a higher risk to develop COM in Chinese Han population.

Although no statistical differences were found between rs1143627 and the risk of developing COM in this Chinese cohort, outcomes of the dominant (*P* = 0.061), homozygous (*P* = 0.080), and heterozygous (*P* = 0.095) models suggested a trend that population with TT and CT genotypes of this polymorphism may be groups in a higher risk to develop COM in Chinese Han population.

With respect to rs1143634 and rs2853550, no significant associations were observed between patients and healthy controls ([Table 2](#tab2){ref-type="table"}).

3.4. Comparisons of Clinical Features among Different Genotypes of the IL-1*β* Gene Polymorphisms in COM Patients {#sec3.4}
-----------------------------------------------------------------------------------------------------------------

As shown in [Table 3](#tab3){ref-type="table"}, significant differences were identified regarding preoperative serum levels of IL-6 among different genotypes of rs16944 (*P* = 0.005) and rs1143627 (*P* = 0.003). Outcomes of multiple comparisons regarding different genotypes of rs16944 among COM patients revealed that the median serum IL-6 level of AG genotype group was significantly higher than that of AA group (*P* = 0.001), with no statistical differences between AA versus GG (*P* = 0.164) or AG versus GG (*P* = 0.093) groups ([Figure 1(a)](#fig1){ref-type="fig"}). In addition, significant difference was found regarding median serum IL-6 level between AA+GG and AG genotype groups (10.51 pg/ml versus 21.10 pg/ml,*P* = 0.004) ([Figure 1(b)](#fig1){ref-type="fig"}).

Likewise, multiple comparisons regarding rs1143627 showed that the median serum IL-6 level of CT genotype group was statistically higher than that of CC group (*P* = 0.0008), with no significant differences between CC versus TT (*P* = 0.149) or CT versus TT (*P* = 0.079) genotype groups ([Figure 2(a)](#fig2){ref-type="fig"}). Additionally, significant difference was also observed regarding median serum IL-6 level between CC and CT+TT genotype groups (7.98 pg/ml versus 17.92 pg/ml,*P* = 0.004) ([Figure 2(b)](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

Outcomes of the current study demonstrated that IL-1*β* gene rs16944 polymorphism may contribute to the elevated susceptibility to COM in Chinese Han population. People with AG genotype of rs16944 may be a group in a higher risk to develop COM. In addition, although the present study did not obtain statistical outcomes regarding rs1143627 polymorphism between patients and healthy controls, there existed a trend that rs1143627 polymorphism may correlate with an increased risk of COM development by outcomes of dominant, homozygous, and heterozygous models.

As mentioned previously, nowadays, COM, mostly arises following trauma or orthopaedic surgery, still represents great challenges and risks for clinicians. It was reported the incidence of infection following open fractures in the long bones ranged between 4% and 64%, with infection recurrence of 20% to even 30% \[[@B19]\]. Its long disease course and inflammatory bone destruction severely affect life qualities of the patients, both physically and psychologically. In a recent study, Huang et al. \[[@B20]\] indicated that COM significantly increased the risk of long-term mortality in the elderly. In addition to the previously mentioned comorbidities, deep venous thrombosis (VTE) \[[@B21]\], end-stage renal disease (ESRD) \[[@B22]\], dementia \[[@B23]\], erectile dysfunction \[[@B24]\] and even mental disorder like depression \[[@B3]\] also appear to be more frequent in COM patients. Moreover, there exists a risk of malignant transformation in patients with COM, though the incidence is low \[[@B25]\]. The primary disease and potential comorbidities increase economic burdens of the patients. A recent survey \[[@B8]\] revealed the treatment costs of infection after tibia fracture fixation were about 6.5 times higher than those without infection (€44, 468 versus € 6,855). Therefore, COM is not only a clinical disorder, but also a social problem.

It is known that occurrence of COM is influenced by external and internal factors. External factors include infection etiology (e.g., trauma, hematogenous spread, and diabetic foot), injury type and degree, situation of soft tissue, etc., whereas internal factors refers to host factors, such as age, smoking, alcoholism, nutrition situation, immune function, etc. \[[@B26]\]. Previous studies mostly focused on the effects of controllable external and internal factors on the incidence of COM and neglected uncontrollable genetic factors. Recently, increasing number of studies revealed potential roles of genetic factors in the pathogenesis of COM, with SNP as an important aspect. Up till now, several clinical investigations have reported significant links between gene SNPs and susceptibility to COM among different ethnicities, such as*VDR* gene \[[@B9]\],*COX-2*gene \[[@B10]\],*tPA*gene \[[@B11]\],*MMP-1* gene \[[@B12]\], and the most frequently reported IL family genes.

Previous studies obtained positive outcomes of IL family gene polymorphisms associate with OM development, including IL-1*α* (rs1800587) \[[@B27], [@B28]\], IL-4 (rs2243248, rs2243250) \[[@B28]\], and IL-6 (rs1800795) \[[@B28]\]. All of the above gene polymorphisms increase the susceptibility to OM. As an important member of IL family cytokines, IL-1*β* has been identified to participate in the pathogenesis of OM in animal experiments \[[@B13], [@B14]\]. Considering the highly polymorphic of IL-1*β* gene as well as the confirmed relationships between IL-1*β* gene polymorphisms and the development of different inflammatory diseases, we hypothesized that IL-1*β* gene SNPs may be correlated with COM.

Outcomes of the current study demonstrated that IL-1*β* gene rs16944 may be related to the increased risk of developing COM in Chinese Han population. Similarly, in a recent study with 39 OM patients and 114 healthy controls, Alves De Souza et al. \[[@B29]\] found that rs16944 with rs2234663 polymorphisms may participate in the development of posttraumatic OM in Brazilian population. However, quite different from their findings of genotype of TT being more frequent in OM patients, we found AA was less while AG was more frequent in COM patients. Two possible reasons may account for the difference. One may lie in the different ethnicities. The other may attribute to the fact that in addition to posttraumatic OM, we also included COM patients resulting from hematogenous spread and diabetic foot. In another study consisting of 52 patients with hematogenous osteomyelitis (HO) and 103 controls, Osman et al. \[[@B30]\] observed that rs16944 SNP may be linked with HO in Saudi population. However, likewise, our findings were also quite different from theirs. They found percentage of genotype GG was lower while AA was higher in patient group than those in controls, and therefore, they concluded AA genotype may be a risk factor of HO. In our study, percentage of AA genotype was lower while AG genotype was higher in patient group, suggesting that AG genotype may a risk factor of COM. With regard to underlying mechanisms of rs16944 polymorphism in the development of COM, we compared preoperative serum levels of different inflammatory biomarkers. Results only showed that serum IL-6 level in AG genotype group was significantly higher than those in AA group and AA+GG group, implying that IL-6 may be one of the mediators in the development of IL-1*β* induced COM.

In this study, we also observed a trend that rs1143627 polymorphism may be linked with increased susceptibility to COM in Chinese Han population, though outcomes of dominant (*P* = 0.061), homozygous (*P* = 0.080), and heterozygous (*P* = 0.095) models were not statistically significant. It was also interesting that serum IL-6 level in CT genotype group was significantly higher than that in CC genotype group. Moreover, serum IL-6 level of CT+TT genotypes group was also statistically higher than CC group. Therefore, on the one hand, a larger sample size is quite necessary. On the other hand, further explorations are required to better understand potential role of IL-6 in the pathogenesis of rs16944 and rs1143627 polymorphisms induced COM.

The present study had several limitations. Firstly, although the sample size of the present study was larger than most of the published studies, it is still far from enough for SNP investigation. In addition, as mentioned previously, pathogenic mechanism for establishment of COM is multifactorial; therefore, larger number of participants should be included in future studies. Secondly, we did not detect serum IL-1 level of each case and therefore, association between IL-1*β* gene polymorphisms and serum IL-1 levels remains unclear. Thirdly, as mentioned previously, in addition to host genetic factors, environmental factors also involve in the pathogenesis of COM. Due to the fact that most of the COM patients included in our study were transferred from local hospitals, detailed medical information (e.g., severity of initial injury, treatment strategy, etc.) before bone infection was unclear. Therefore, we cannot perform further analysis regarding the role of such external factors in the development of COM. Fourthly, this study was a preliminary report. Further studies should be conducted for detailed mechanisms underlying this phenomenon.

In summary, the present study found that IL-1*β* gene rs16944 polymorphism may be correlated with increased risk of developing COM in Chinese Han population. People with genotype of AG may suffer from a higher susceptibility to COM.
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###### 

Forward, reverse, and extension primers of the 4 tag SNPs for PCR.

  SNPs        Forward and reverse primers (5′-3′)   Extension primers (5′-3′)
  ----------- ------------------------------------- ---------------------------------------------
  rs16944     F: ATGTGGGACAAAGTGGAAGAC              TTTTTTTTTTTTCTTGGGTGCTGTTCTCTGCCTC
              R: AATTTTCTCCTCAGAGGCTC               
  rs1143627   F: CCACCAATACTCTTTTCCCC               TTTTTTTTTTTTTTTTTCCTACTTCTGCTTTTGAAAGC
              R: CCTTAGCACCTAGTTGTAAG               
  rs1143634   F: CTACTGGTGTTGTCATCAGAC              TTTTTTTTTTTTTTTTTTAAGCCTCGTTATCCCATGTGTC
              R: AGCTTTTTTGCTGTGAGTCCC              
  rs2853550   F: ACTAAAGCCCACTCCTCATTG              TTTTTTTTTTTTTTTTTTTTTCAGAAGGATATTCAGTGCACAT
              R:ATAGCGCTTGCTCAACAGATG               

SNPs: single nucleotide polymorphisms.

PCR: polymerase chain reaction.

###### 

Comparisons of genotype distribution, allele frequency, and genetic models between COM patients and healthy controls.

  SNP ID         Items                          Patients      Healthy controls   *P* value               OR (95%CI)
  -------------- ----------------- ------------ ------------- ------------------ ----------------------- ---------------------
  rs16944        Genotype (n, %)   AA           40 (17.17)    52 (26.0)          0.079                   NA
                                   AG           120 (51.50)   90 (45.0)                                   
                                   GG           73 (31.33)    58 (29.0)                                   
                 Allele            G vs. A      266/200       206/194            0.100                   1.253 (0.958-1.638)
  Dominant       GG+AG vs. AA      193/40       148/52        **0.026**          1.698 (1.065-2.707)     
  Recessive      GG vs. AA+AG      73/160       58/142        0.586              1.122 (0.742-1.696)     
  Homozygous     GG vs. AA         73/40        58/52         0.071              1.643 (0.958-2.818)     
  Heterozygous   AG vs. AA         120/40       90/52         **0.030**          1.733 (1.055-2.847)     
  rs1143627      Genotype (n, %)   CC           42 (18.03)    51 (25.5)          0.163                   NA
                                   CT           118 (50.64)   94 (47.0)                                   
                 TT                73 (31.33)   55 (27.5)                                                
  Allele         T vs. C           264/202      204/196       0.096              1.256 (0.960-1.642)     
  Dominant       TT+CT vs. CC      191/42       149/51        0.061              1.557 (0.980-2.473)     
  Recessive      TT vs. CC+CT      73/160       55/145        0.368              1.211 (0.798-1.838)     
  Homozygous     TT vs. CC         73/42        55/51         0.080              1.620 (0.944-2.779)     
  Heterozygous   CT vs. CC         118/42       94/51         0.095              1.520 (0.930-2.485)     
  rs1143634      Genotype (n, %)   CC           229 (98.28)   194 (97.0)         0.524                   NA
                                   CT           4 (1.72)      6 (3.0)                                     
                                   TT           0 (0.0)       0 (0.0)                                     
                 Allele            T vs. C      4/462         6/394              0.574                   0.569 (0.159-2.029)
  Dominant       TT+CT vs. CC      4/229        6/194         0.402              0.577 (0.160-2.084)     
  Recessive      TT vs. CC+CT      0/233        0/200         NA                 NA                      
  Homozygous     TT vs. CC         0/229        0/194         NA                 NA                      
  Heterozygous   CT vs. CC         4/229        6/194         0.402              0.577 (0.160-2.084)     
  rs2853550      Genotype (n, %)   CC           206 (88.41)   171 (85.5)         0.281                   NA
                                   CT           27 (11.59)    27 (13.5)                                   
                 TT                0 (0.0)      2 (1.00)                                                 
  Allele         T vs. C           27/439       31/369        0.251              0.732 (0.429-1.249)     
  Dominant       TT+CT vs. CC      27/206       29/171        0.315              0.749 (0.425-1.317)     
  Recessive      TT vs. CC+CT      0/233        2/198         0.999              0.000 (0.000-* *-* *-   
  Homozygous     TT vs. CC         0/206        2/171         0.999              0.000 (0.000-* *-* *-   
  Heterozygous   CT vs. CC         27/206       27/171        0.459              0.805 (0.454-1.429)     

SNP: single-nucleotide polymorphism; OR: odds ratio; CI: confidence interval. NA: not available.

###### 

Comparisons of clinical features among different genotypes of the IL-1*β* gene polymorphisms in COM patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Items                                rs16944                rs1143627              rs1143634              rs2853550                                                                                                                                                                                        
  ------------------------------------ ---------------------- ---------------------- ---------------------- ----------- ---------------------- ---------------------- ---------------------- ----------- ---------------------- ---------------------- ------- ---------------------- ---------------------- -------
  Age Median (IQR)                     42.50 (27.00, 50.00)   37.50 (24.00, 52.00)   39.00 (28.50, 48.50)   0.696       42.00 (27.00, 50.00)   37.50 (24.00, 52.25)   39.00 (28.50, 48.50)   0.838       39.00 (26.00, 50.00)   48.50 (39.50, 59.75)   0.182   39.00 (26.00, 50.25)   38.00 (27.00, 49.00)   0.769

  Sex ratio (M/F)                      28/12                  100/20                 57/16                  0.185       30/12                  98/20                  57/16                  0.263       182/47                 3/1                    1.000   163/43                 22/5                   0.776

  Positive rate of culture (%) (E/T)   68.97 (20/29)          65.17 (58/89)          61.82 (34/55)          0.803       67.74 (21/31)          65.52 (57/87)          61.82 (34/55)          0.839       64.91 (111/171)        50 (1/2)               1.000   62.18 (97/156)         88.24 (15/17)          0.033

  Polymicrobial infection (%) (E/T)    30.00 (6/20)           18.97 (11/58)          20.59 (7/34)           0.597       28.57 (6/21)           19.30 (11/57)          20.59 (7/34)           0.682       21.62 (24/111)         0 (0/1)                1.000   21.65 (21/97)          20 (3/15)              1.000

  WBC (×10^9^/L)  \                    7.66 (6.33, 9.07)      7.34 (5.59, 9.36)      6.93 (6.11, 8.51)      0.414       7.66 (6.38, 9.16)      7.34 (5.55, 9.28)      6.93 (6.11, 8.51)      0.346       7.24 (5.94, 8.93)      7.30 (5.46, 7.90)      0.660   7.25 (6.03, 8.77)      7.39 (5.41, 9.99)      0.833
  Median (IQR)                                                                                                                                                                                                                                                                                               

  CRP (mg/L) Median (IQR)              3.99 (1.67, 33.36)     6.20 (2.28, 21)        7.65 (2.41, 18.58)     0.646       3.99 (1.48, 29.61)     6.20 (2.32, 21.20)     7.65 (2.41, 18.58)     0.567       6.25 (2.24, 19.70)     6.51 (2.31, 14.18)     0.844   6.57 (2.37, 19.35)     4.67 (1.57, 17.56)     0.459

  PCT (ng/ml) Median (IQR)             0.037 (0.020, 0.053)   0.035 (0.023, 0.069)   0.038 (0.026, 0.051)   0.894       0.038 (0.020, 0.053)   0.035 (0.023, 0.070)   0.038 (0.026, 0.051)   0.912       0.037 (0.023, 0.062)   0.030 (0.024, 0.038)   0.499   0.037 (0.024, 0.062)   0.027 (0.020, 0.051)   0.273

  IL-6 (pg/ml) Median (IQR)            7.98 (3.73, 18.17)     21.10 (8.71, 74.49)    12.44 (4.34, 53.46)    **0.005**   7.98 (3.60, 20.08      21.1 (8.84, 74.50)     12.44 (4.34, 53.46)    **0.003**   15.39 (6.55, 59.78)    24.29 (4.05, 38.95)    0.781   14.76 (6.22, 59.35)    24.67 (8.10, 77.43)    0.379

  TNF-*α* (pg/ml) Median (IQR)         9.67 (7.67, 11.20)     9.78 (7.56, 13.05)     8.73 (7.21, 11.53)     0.494       9.7 (8.04, 11.60)      9.42 (7.55, 13.10)     8.73 (7.21, 11.53)     0.510       9.26 (7.38, 12.00)     9.04 (8.07, 12.77)     0.872   9.16 (7.50, 12.00)     10.40 (6.65, 13.50)    0.698

  SAA (mg/L) Median (IQR)              7.40 (2.45, 28.25)     9.40 (4.20, 37.40)     5.00 (3.23, 61.75)     0.776       8.15 (2.48, 26.58)     8.55 (4.18, 37.53)     5.00 (3.23, 61.75)     0.861       7.60 (3.30, 29.05)     272.30                 0.135   8.30 (3.33, 30.33)     5.25 (2.85, 222.05)    0.858
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COM: chronic osteomyelitis; IQR: interquartile range; M/F: male/female; E/T: events/total; WBC: white blood cell count; CRP: C-reactive protein; PCT: procalcitonin; IL-6: interleukin-6; TNF-a: tumor necrosis factor-a; SAA: serum amyloid A.
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